Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 6, Issue 1, 2002, Pages 9-14

  Bartkó, György ^a   Váradi, Hedvig ^a   Simon, Lajos ^a   Linka, Emese ^a   Tüske, Tamás ^a   Szabó, Tibor ^a   Sántha, Judit ^a  

^a Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

Author keywords

Olanzapine; Patient satisfaction; Quetiapine; Risperidone; Switching

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; DAILY LIFE ACTIVITY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SYMPTOM; TREATMENT OUTCOME;

EID: 0036117709     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/136515002753489362     Document Type: Article

References (31)

1. The aims of antipsychotic medications - What are they and are they being achieved?
2. New atypical antipsychotic agents
3. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients
4. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement
5. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures
6. Subjective response to neuroleptics in schizophrenia
7. Patients' subjective experiences on antipsychotic medications: Implications for outcome and quality of life
8. An overview of patient satisfaction with psychiatric treatment
9. Patient satisfaction: A valid concept?
10. Patient satisfaction in mental health care. Evaluating an evaluative method
11. Patient satisfaction with, and acceptability of atypical antipsychotics
12. Patient satisfaction: A valid index of quality of care in a psychiatric service
13. Patients' views towards care received from psychiatrists
14. A self-rating to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life, compliance and other clinical variables
15. Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability
16. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative ability
17. Schizophrenic and medical inpatients as informed drug consumers
18. Drug defaults among schizophrenic patients
19. Causes of neuroleptic noncompliance
20. A two-year prospective study of treatment compliance in patients with schizophrenia
21. Clinical outcomes of pharmacotherapy for schizophrenia and implications for health economics
22. Impact of newer antipsychotics on outcomes in schizophrenia
23. Quality of life issues in medicated schizophrenics: Therapeutic and research implications
24. A conceptual model of quality of life in schizophrenia: Description and preliminary validation
25. Antipsychotic tolerability: The attitudes and perceptions of medical professionals, patients and caregivers towards the side-effects of antipsychotic therapy
26. Patient satisfaction and acceptability of long-term treatment with quetiapme
27. Overcoming challenges in the management of schizophrenia
28. Switching antipsychotic medications
29. Switching antipsychotic therapies
30. Clinical global impression